google-site-verification: googlec7193c3de77668c9.html

Researchers develop new test for early osteoarthritis diagnosis

osteoarthritis
Credit: CC0 Public Domain

Diagnosing osteoarthritis often occurs in the late stages when cartilage degradation is severe, making it difficult to distinguish it from other types of arthritis and to determine the best treatment plan.

In work published in the Journal of Orthopaedic Research, investigators have developed and tested a new diagnostic test that uses two markers found in the synovial fluid of patients’ joints.

After assessing levels of cartilage oligomeric matrix protein and interleukin‐8, the team came up with an algorithm based on the ratio of these two markers and validated its efficacy in differentiating osteoarthritis from inflammatory arthritis in 171 human knee synovial fluid specimens.

“This study addresses an unmet need for objective diagnosis of osteoarthritis to improve clinical decision-making and patient outcomes,” said corresponding author Daniel Keter, BA, of CD Diagnostics, A Division of Zimmer Biomet.

More information:
Synovial Fluid Dual-Biomarker Algorithm Accurately Differentiates Osteoarthritis from Inflammatory Arthritis, Journal of Orthopaedic Research (2024). DOI: 10.1002/jor.26005

Citation:
Researchers develop new test for early osteoarthritis diagnosis (2024, December 18)
retrieved 18 December 2024
from https://medicalxpress.com/news/2024-12-early-osteoarthritis-diagnosis.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Advertisements




medicalxpress.com

Views: 1

See also  'Ozempic teeth' concerns grow as patients report dental problems from weight-loss drugs

Check Also

A mayor in Japan announced her maternity leave – and got the whole country talking

Although there is statutory maternity and paternity leave – which guarantees time off and partial …

FDA approves Tzield for children with new stage 3 type 1 diabetes

[ The U.S. Food and Drug Administration has granted accelerated approval to Sanofi’s Tzield (teplizumab-mzwv) …

Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models

[ A new study led by researchers at The University of Texas MD Anderson Cancer …

Leave a Reply

Available for Amazon Prime